Effects of 17β-Estradiol and Phytoestrogen α-Zearalanol on Tissue Factor in Plasma of Ovariectomized Rats and HUVECs

Wen Wang；Guang-Jin Zhu；Shu-Yu Zu

17β-estradiol ； α-zearalanol ； tissue factor ； ovariectomized rats ； HUVECs

The Chinese Journal of Physiology

47卷2期（2004 / 06 / 01）

67 - 72

英文

In the present study, the effects of 17β-estradiol (E2) and phytoestrogen α-zearalanol (ZAL) on tissue factor (TF) in plasma of ovariectomized (OVX) rats and human umbilical vein endothelial cells (HUVECs) were investigated. OVX rats were injected intramuscularly twice a week with E2 (1mg/kg) or ZAL (1mg/kg) for five weeks. The concentrations of plasma E2 were measured by radioimmunoassay. The TF levels of plasma were assayed by enzyme-linked immunosorbent assay (ELISA). HUVECs were exposed to E2 or ZAL for 48 h. TF protein and mRNA were assayed by ELISA and RT-PCR, respectively. Nuclear proteins of HUVECs opposed to E2 or ZAL for 8 h were extracted to assay transcription factors activator protein-l (AP-1) and nuclear factor-κB (NF-κB) by Western blot. Both E2 and ZAL were found to decrease plasma TF levels of OVX rats significantly. E2 or ZAL were also found down-regulate the expression of TF protein and mRNA in HUVECs. Moreover, both E2 and ZAL might decrease AP-l and NF-κB levels. These results suggest that both E2 and ZAL have inhibitory effects on TF in plasma of OVX rats and HUVECs, which may then contribute to their protective effects on cardiovascular diseases.

1. Aune, B.,Oian, P.,Omsjo, I.,Osterud, B.(1995).Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood-A beneficial effect on atherogenesis and thrombus formation?.Am. J. Obstet. Gynecol,173,1816-1820.
2. Chae, C.U.,Ridker, P.M.,Manson, J.E.(1997).Postmenopausal hormone replacement therapy and cardiovascular disease.Thromb. Haemost,78,770-780.
3. Chiu, J.J.,Lee, P.L.,Lee, C.I.,Chen, L.J.,Chen, C.N.,Ko, Y.C.,Lien, S.C.(2002).Shear stress attenuates tumor necrosis factor-α-induced monocyte chemotactic protein-1 expressions in endothelial cells.Chinese J. Physiol,45,167-176.
4. Dai, S.L.,Duan, J.,Lu, Y.,Cheng, J.,Ren, J.,Zhang, Y.,Zhao, X.,Zhang, L.,Wu, Y.,Ge, Q.(2002).The 24th Annual scientific sessions, North American section of the international society for heart research.Madison, USA:
5. Falciani, M.,Gori, A.M.,Fedi, S.,Chiarugi, L.,Simonetti, I.,Dabizzi, R.P.,Prisco, D.,Pepe, G.,Abbate, R.,Gensini, G.F.,Neri Semen, G.G.(1998).Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.Thromb. Haemost,78,495-499.
6. Gao, Y.M.,Zhu, G.J.(2000).Effects of tumor necrosis factor α and angiotensin II on expression of tissue factor in human vascular endothelial cells.Basic Med. Clin,20,126-129.
7. Grimes, D.A.,Lobo, R.A.(2002).Perspectives on the women`s health initiative trial of hormone replacement therapy.Obstet. Gynecol,100,1344-1353.
8. Holschermann, H.,Terhalle, H.M.,Zakel, U.,Maus, U.,Parviz, B.,Tillmanns, H.,Haberbosch, W.(1999).Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives.Thromb. Haemost,82,1614-1620.
9. Iochmann, S.,Reverdian-Moalic, P.,Beaujean, S.,Rideau, E.,Lebranchu, Y.,Bardos, P.,Gruel, Y.(1999).Fast dection of tissue factor and tissue factor pathway inhibitor messenger RNA in endothelial cells and monocytes by sensitive reverse transcription-polymerase chain reaction.Thromb. Res,94,165-173.
10. Ishii, H.,Takada, K.,Higuchi, T.,Sugiyama, J.(2000).Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-l.Thromb. Haemost,84,712-721.
11. Jaffe, E.A.,Nachman, R.L.,Becker, C.G.,Minick, C.R.(1973).Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.J. Clin. Invest,52,2745-2756.
12. Koh, K.K.(2002).Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal woolen.Int. J. Hematol,76(2),44-46.
13. Koh, K.K.,Kang, M.H.,Jin, D.K.,Lee. S. K.,Aim. J.Y.,Hwang, H.Y.,Yang, S.H.,Kim, D.S.,Ahn, T.H.,Shin, E.K.(2001).Vascular effects of estrogen in type II diabetic postmenopausal women.J. Am. Coil. Cardiol,38,1409-1415.
14. Lobo, R.A.(1995).Benefits and risks of estrogen replacement therapy.Am. J. Obstet. Gynecol,173,982-990.
15. Mackman, N.(1997).Regulation of the tissue factor gene.Thromb. Haemost,78,747-754.
16. Mammen, E.F.(2000).Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease.Heniatoi. Oncoi. Chn. North Am,14,1045-1059.
17. Martin, D.M.,Wiiger, M.T.,Prydz, H.(1998).Tissue factor and biotechnology.Thromb. Res,90,1-25.
18. Rauch, U.,Nemerson, Y.(2000).Circulating tissue factor and thrombosis.Curr. Opin. Hematol,7,273-277.
19. Reid, R.L.(2000).Progestins in hormone replacement therapy: Impact on endometrial and breast cancer.J. SOGO,22,677-681.
20. Rosano, G.M.,Sarrel, P.M.,Poole-Wilson, P.A.,Collins, P.(1993).Beneficial effect of on estrogen on exercise-induced myocardial ischaemia in women with coronary artery disease.Lancet,342,133-136.
21. Simoncini, T.,Maffei, S.,Basta, G.,Barsacchi, G.,Genazzani, A.R.,Liao, J.K.,Caterina, R.(2000).Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms.Circ. Res,87,19-25.
22. Stampfer, M.J.,Coldity, G.A.(1991).Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemio logic evidence.Prevent. Med,20,47-63.
23. Young R.L.,Goepfert, AR.,Goldzieher, H.W.(1991).Estrogen re placement therapy is not conducive of venous thromboembolism.Maturitas,13,189-192.